Clinical Trial Update: Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease [Phase 4]

View source ↗

Summary

Clinical trial for dapagliflozin in children with proteinuric chronic kidney disease was withdrawn after Phase 4.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Proteinuria

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Children's Hospital of Fudan University | Conditions: Proteinuria, Chronic Kidney Diseases | Phase 4 | Status: WITHDRAWN